Search

Your search keyword '"WEILAI XU"' showing total 25 results

Search Constraints

Start Over You searched for: Author "WEILAI XU" Remove constraint Author: "WEILAI XU" Topic business.industry Remove constraint Topic: business.industry
25 results on '"WEILAI XU"'

Search Results

1. Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes

2. Real‐world data of chronic myelomonocytic leukemia: A chinese single‐center retrospective study

3. Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study

4. Mutation status and burden can improve prognostic prediction of patients with lower‐risk myelodysplastic syndromes

5. Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting

6. Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study

7. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial

8. Clinical and biological characteristics of acute myeloid leukemia with 20–29% blasts: a retrospective single-center study

9. Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy

10. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

11. A Real World Study of Venetoclax Combined with Azacitidine in 64 Chinese Patients Newly Diagnosed Acute Myeloid Leukemia

12. Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone

13. Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases

14. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy

15. Towards Generating Stylistic Dialogues for Narratives using Data-Driven Approaches

16. The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts

17. Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB

18. Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

19. The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes

20. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia

21. Anaplastic large-cell lymphoma with atypical chromosomal translocation t(2;5) and hypophyseal tumor

22. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics

23. Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience

24. Acquired Robertsonian translocation is not always suggestive of poor prognosis: a case of acquired Rob(13;14) in Philadelphia chromosome-negative cells of chronic myelogenous leukemia

25. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia

Catalog

Books, media, physical & digital resources